Key statistics dashboard for Ovid Therapeutics Inc. (OVID). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infa...
Stock Data
| Price | $2.68 |
| Market Cap | $500M |
| Beta | -0.03 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -5.65 |
| Price / Book | 0.95 |
| P/S | 319.52 |
| P/FCF | -9.23 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 100.00% |
| EBIT Margin | -2257.68% |
| EBITDA Margin | -2252.37% |
| Operating Margin | -3686.67% |
| Net Margin | -2178.90% |
Financial Health
| Current Ratio | 12.39 |
| Quick Ratio | 12.39 |
| Cash Ratio | 1.13 |
| Debt / Equity | 0.06 |
| Debt / Assets | 5.48% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.02 |
| Book Value per share | 2.85 |
| Cash per share | 1.59 |
| FCF per share | -0.74 |
| Tangible Book Value per share | 2.85 |
| Dividend per share | 0.00 |
Related companies: CLNN · CNTB · CNTX · IFRX · IMA · KLRS · MGNX
Explore sector: Healthcare · Biotechnology
More sections of OVID: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks